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ABSTRACT
We report final analysis outcomes from the phase 3 HELIOS study (NCT01611090). Patients with
relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma without deletion
17p (n¼ 578) were randomized 1:1 to 420mg daily ibrutinib or placebo plus 6 cycles of benda-
mustine plus rituximab (BR), followed by ibrutinib or placebo alone. Median follow-up was
63.7months. Median investigator-assessed progression-free survival was longer with ibrutinib plus
BR (65.1months) than placebo plus BR (14.3months; hazard ratio [HR] 0.229 [95% confidence inter-
val (CI) 0.183–0.286]; p< .0001). Despite crossover of 63.3% of patients from the placebo plus BR
arm to ibrutinib treatment upon disease progression, ibrutinib plus BR versus placebo plus BR
demonstrated an overall survival benefit (HR 0.611 [95% CI 0.455–0.822]; p¼ .0010; median not
reached in either arm). Long-term follow-up data confirm the survival benefit of ibrutinib plus BR
over BR alone. Safety profiles were consistent with those known for ibrutinib and BR.
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Ibrutinib, administered orally once daily, is approved
to treat adults with various B-cell malignancies in the
United States, European Union, and other countries
[1–3]. This first-in-class covalent inhibitor of Bruton’s
tyrosine kinase (BTK) has changed the treatment land-
scape for patients with chronic lymphocytic leukemia
(CLL)/small lymphocytic lymphoma (SLL) [4–7] and is
one of the preferred treatments for patients with or
without deletion 17p/TP53 mutation, who have previ-
ously untreated or relapsed/refractory (R/R) disease [6].
Ibrutinib was evaluated as a single-agent treatment
in patients with R/R CLL/SLL in an open-label random-
ized, multicenter phase 3 trial (RESONATETM) [8–10]. In
the final analysis of the study (median follow-up,
65.3months in the ibrutinib arm), patients who
received ibrutinib (n¼ 195) versus ofatumumab
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(n¼ 196), including those with high-risk genomic fea-
tures, had a superior progression-free survival (PFS;
hazard ratio [HR], 0.148; 95% confidence interval [CI]
0.113–0.196; p< .0001) [10]. Additionally, although
68% of patients in the ofatumumab arm crossed over
to the ibrutinib arm, an overall survival (OS) benefit
with ibrutinib was seen (HR 0.639; 95% CI 0.418–0.975;
censored for the crossover).
Before the availability of BTK inhibitors like ibrutinib,
which target the B-cell receptor signaling pathway, a
chemoimmunotherapy regimen of bendamustine (an
alkylating agent) plus rituximab (an anti-CD20 antibody)
was commonly used for patients with R/R CLL [11,12].
In a phase 2 study of 6 cycles of bendamustine plus
rituximab (BR) in patients with R/R CLL, overall response
rate (ORR) was 59% (complete response [CR], 9%),
median PFS was 15.2 months, and median OS was 33.9
months [13]. The HELIOS study was designed to deter-
mine whether ibrutinib therapy provided additional
benefit when combined with BR as a chemoimmuno-
therapy backbone. In a prior phase 1b multicenter
study evaluating the safety and efficacy of continuous
ibrutinib plus 6 cycles of BR in 30 patients with R/R
CLL, the ORR was high (93.3%), with 70.3% of patients
remaining progression free at the 36-month land-
mark [14].
Here, we report outcomes of the final analysis of
HELIOS, a phase 3, randomized, double-blind, placebo-
controlled study of ibrutinib plus 6 cycles of BR in
578 patients with R/R CLL/SLL (median follow-up,
63.7months); findings from interim [15] and 3-year
analyses [16] were previously reported.
Patients and methods
The HELIOS study (NCT01611090) was conducted at
133 sites in 21 countries. The protocol was approved
by an independent ethics committee/institutional
review board at each site [15] and performed accord-
ing to principles of the Declaration of Helsinki and
guidelines for Good Clinical Practice. Patients provided
informed consent before participation.
Patient eligibility
As previously described [15,16], eligible patients were
aged 18 years with active CLL/SLL disease meeting
the International Workshop on Chronic Lymphocytic
Leukemia 2008 criteria [17] for treatment. Included
patients also had R/R disease following 1 prior lines
of therapy (including 3% of patients in each arm who
received BR [15]); an Eastern Cooperative Oncology
Group performance status of 0–1; measurable lymph
node disease (>1.5 cm) by computed tomography (CT)
scan; and adequate liver and kidney function. Patients
with deletion 17p (20% of blood/bone marrow cells
examined by fluorescent in situ hybridization) were
excluded due to the known poor response to BR by
patients with this deletion. TP53 mutational testing
was not performed or included in the study’s exclu-
sion criteria.
Study design
Patients were randomly assigned (1:1) to treatment
with ibrutinib (420mg daily) plus BR (6 cycles of
bendamustine [70mg/m2 intravenously on Days 2–3
of Cycle 1 and Days 1–2 of Cycles 2–6] and rituximab
[375mg/m2 on Day 1 of Cycle 1 and 500mg/m2 on
Day 1 of Cycles 2–6]) or placebo plus BR (Figure 1).
Patients then continued ibrutinib or placebo treatment
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Figure 1. Study design and follow-up assessments. IRC: independent review committee; PD: progressive disease. aDeletion 17p in
20% of examined cells. bStratified by purine analog refractory status (failure to respond or relapse in 12 months) and prior
lines of therapy (1 line versus >1 line). cSimilar dosing to Fischer et al. [13]; bendamustine: 70mg/m2 intravenously on Days 2–3
in Cycle 1 and Days 1–2 in Cycles 2–6; rituximab: 375mg/m2 on Day 1 of Cycle 1 and 500mg/m2 on Day 1 of Cycles 2–6.
dAccording to 2008 International Workshop on Chronic Lymphocytic Leukemia criteria (Hallek et al. [17]).
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Following the prespecified interim analysis (March
2015), the Data and Safety Monitoring Board recom-
mended unblinding the study, therefore, placebo
treatment was discontinued for patients in the pla-
cebo plus BR arm. Treatment-emergent adverse event
(TEAE) reporting for this arm was also discontinued at
this time; these patients had continued disease evalu-
ation and follow-up and were permitted to cross over
to ibrutinib after confirmed disease progression
(Figure 1). Safety data are reported for the ibrutinib
plus BR arm; adverse events (AEs) occurring in patients
who crossed over from the placebo plus BR arm to
ibrutinib arm are excluded.
Endpoints and follow-up assessments
Endpoints investigated in this final analysis included
investigator-assessed PFS, OS, ORR, and safety (Figure
1). PFS2 (time interval from randomization to either
progressive disease on next-line treatment, death, or
the start of subsequent antineoplastic therapy if pro-
gressive disease was not reported) was also
investigated.
Minimal residual disease (MRD) testing was first per-
formed on the bone marrow at the time of a radio-
logically documented CR, and subsequently on
peripheral blood every 12weeks [15,16]. Due to the
long half-life of anti-CD20 monoclonal antibodies such
as rituximab in peripheral blood, the first bone mar-
row sample was acquired to mitigate cross-reactivity
[15]. Testing was done at a central laboratory by flow
cytometry using an eight-color panel of antibodies in
line with the EuroFlow panel [15,16,18]. A protocol
amendment following the interim analysis enabled
MRD analysis for all patients with partial response (PR)
or better [16]. The patient proportion with
undetectable MRD increased through to the 3-year fol-
low-up but plateaued thereafter, therefore data collec-
tion was terminated shortly afterwards.
Statistical analyses
All randomized patients were included in the efficacy
analysis (intent-to-treat population). Patients who
received 1 dose of the study drug were included in
the safety analysis (safety population).
In the interim analysis, overall concordance
between independent review committee (IRC)-
assessed and investigator-assessed progressive disease
was 90% and 85% in the ibrutinib plus BR and pla-
cebo plus BR arms, respectively [15]. PFS analyses
were performed using IRC assessments in the interim
analysis and investigator assessments in the long-term
analysis. For patients alive at the time of this analysis,
OS – defined as the time interval from randomization
to death, regardless of cause – was censored at the
last known date they were alive.
PFS distribution was estimated using the
Kaplan–Meier method and a stratified log-rank test.
Cox-proportional hazards model was used to calcu-
late HR.
Results
Patient demographics and baseline characteristics
were well balanced between treatment arms and pre-
viously reported [15].
Treatment exposure and patient disposition
At the final analysis, median follow-up was
63.7months (95% CI 62.8–64.3; range 0.1–74.5; Table
Table 1. Patient disposition for the intent-to-treat population.
Ibrutinib plus BR (n¼ 289) Placebo plus BRa (n¼ 289) Total (N¼ 578)








Study treatment phase disposition, n (%)
Did not receive study drug 2 (0.7) 2 (0.7) 4 (0.7)
Discontinued study treatment 287 (99.3) 287 (99.3) 574 (99.3)
Primary reason for discontinuation,b n (%)
Investigator or sponsor decision (including end of follow-up on trial)c 136 (47.1) 84 (29.1) 220 (38.1)
Progressive disease or relapse 55 (19.0) 148 (51.2) 203 (35.1)
Adverse event 58 (20.1) 34 (11.8) 92 (15.9)
Withdrawal of consent 23 (8.0) 13 (4.5) 36 (6.2)
Death 16 (5.5) 9 (3.1) 25 (4.3)
Lost to follow-up 1 (0.3) 1 (0.3) 2 (0.3)
Crossover to ibrutinib – 183 (66.3) –
BR: bendamustine and rituximab; CI: confidence interval; TEAEs: treatment-emergent adverse events.
aFollowing the prespecified interim analysis, placebo treatment was discontinued on 10 March 2015, as was the reporting of TEAEs for the placebo arm;
these patients had continued disease evaluation and follow-up and were permitted to cross over to ibrutinib after confirmed disease progression.
bIncludes patients who did not receive study medication.
cIncludes patients who rolled over to the phase 3b access study (CAN3001) or commercial ibrutinib.
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1) overall, and similar for patients in both treatment
arms. Median time on treatment in the ibrutinib plus
BR arm (n¼ 287) was 55.7months (range 0.2–72.9). As
placebo treatment was discontinued at the interim
analysis, median time on treatment in the placebo
plus BR arm (n¼ 287) was 14.3months
(range 0.2–30.6).
At the final analysis, 183 (63.3%) patients with con-
firmed disease progression crossed over from the pla-
cebo arm to single-agent ibrutinib treatment. The
most common reasons for treatment discontinuation
in the ibrutinib plus BR arm were investigator/sponsor
decision (136 of 289 patients [47.1%]; mainly consist-
ing of patients reaching study end and rolling over to
an open-label access study, where ibrutinib was con-
tinued), AEs (58 patients [20.1%]; Table 1), and pro-
gressive disease/relapse (55 patients [19.0%]). In the
placebo plus BR arm, most common reasons for treat-
ment discontinuation included progressive disease/
relapse (148 of 289 patients [51.2%]) and investigator/
sponsor decision (84 patients [29.1%]; mainly following
unblinding at the interim analysis).
Progression-free survival and overall survival
Median PFS for the ibrutinib plus BR arm at final ana-
lysis was 65.1months (n¼ 289); substantially longer
than for the placebo plus BR arm (median
14.3months; n¼ 289; HR 0.229 [95% CI 0.183–0.286];
p< .0001; Figure 2). The 60-month PFS rate was 52.7%
in the ibrutinib plus BR arm and 8.2% in the placebo
plus BR arm.
At the final 5-year analysis, the OS advantage for
patients in the ibrutinib plus BR arm versus placebo
plus BR arm was maintained despite crossover of 183
patients (63.3%) from the placebo plus BR arm to ibru-
tinib treatment (HR 0.611 [95% CI 0.455–0.822];
p¼ .0010; Figure 3). Median OS was not reached in
either group; the 60-month OS rate was 75.7% for
ibrutinib plus BR versus 61.2% for placebo plus BR.
Median PFS2 was not reached in the ibrutinib plus
BR arm, notably longer than in the placebo plus BR
arm (63.0months; HR 0.594 [95% CI 0.453–0.778];
p¼ .0001). At the time of data cutoff, 52 (18.1%)
patients in the ibrutinib plus BR arm received at least
one subsequent antineoplastic therapy. Of the patients
in the placebo plus BR arm who did not receive ibruti-
nib as first subsequent therapy as part of crossover,
60 (20.9%) received other subsequent therapy. The
most commonly administered subsequent therapies in
the ibrutinib plus BR and placebo plus BR arms,
respectively, were monoclonal antibodies (7.7% and
12.2%; mainly rituximab), nitrogen mustard analogues
(7.7% and 10.8%; mainly cyclophosphamide), cortico-
steroids (4.2% and 10.1%), anthracyclines (1.4% and
6.6%; mainly doxorubicin), and other antineoplastic
agents (6.6% and 4.2%; including venetoclax: 4.5%
and 2.4%). In addition, 3 (1.0%) and 6 (2.1%) patients
in the ibrutinib plus BR and placebo plus BR arms
respectively, received allogenic stem cell transplant as
Months
0 4
HR (95% CI), 0.229 (0.183–0.286); p<.0001
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Ibrutinib plus BR Placebo plus BR Median
Figure 2. Investigator-assessed PFS for ibrutinib plus BR versus placebo plus BR.
FINAL 5-YEAR HELIOS STUDY FINDINGS 3191
subsequent therapy. Chemotherapy agents and anti-
CD20 antibodies were commonly administered
together in a variety of regimens, including R-CHOP
for treatment of Richter’s transformation. Of the 13
patients in the ibrutinib plus BR arm who received
subsequent venetoclax or venetoclax plus CD20 anti-
body treatment, 9 patients received it as first subse-
quent therapy to ibrutinib; best response was CR (3
subjects), PR (3 subjects), not reported (3 subjects).
For patients who received a subsequent antineo-
plastic therapy, the time from start of the first subse-
quent therapy to progression or death was longest
for patients who received ibrutinib subsequent to pla-
cebo plus BR (median not reached, 95% CI 45.57
months –not evaluable). For those who received sub-
sequent therapy other than ibrutinib, the median time
from start of the first subsequent therapy to progres-
sion or death was similar for patients previously on
ibrutinib plus BR and those previously on placebo plus
BR (median (95% CI) 9.43months (3.22 22.08), and
9.17months (1.68 15.15), respectively).
Overall response rate
Investigator-assessed ORR was 87.2% for ibrutinib plus
BR versus 66.1% for placebo plus BR (p< .0001).
Responses deepened over time: CR/CR with incom-
plete bone marrow recovery rate (CRi) in the ibrutinib
arm increased from 21.5% (62/289) in the interim ana-
lysis to 38.1% (110/289) in the 3-year analysis and
40.8% (118/289) in the final analysis. The patient pro-
portion with undetectable MRD in peripheral blood or
bone marrow in the final analysis was 28.7% in the
ibrutinib plus BR arm (similar to the 3-year analysis
[26.3%] [16], as MRD testing was ceased shortly after
the 3-year analysis).
Safety
TEAEs for the ibrutinib plus BR arm were consistent
with previous reports [15, 16]. Most patients (90.2%)
had at least 1 grade 3 TEAE and these occurred
most frequently in the first 6months of treatment
(Table 2). Similar to the 3-year results, 69.0% of
patients had serious TEAEs (any grade) and 20.2% had
TEAEs leading to ibrutinib discontinuation (61.3% and
16.0%, respectively, in the 3-year analysis). During the
first 6months in the ibrutinib plus BR arm, 7.7% of
patients discontinued ibrutinib due to AEs; this rate
decreased over time with continued single-agent ibru-
tinib treatment (Table 2).
The incidence of the TEAE of clinical interest, major
hemorrhage (any grade), was 5.6% in the ibrutinib
plus BR arm during the study duration, including 3
(1.0%) patients with grade 5 major hemorrhage (1
patient with a history of hypertension and an abdom-
inal aortic aneurysm had an abdominal aortic aneur-
ysm rupture, 1 patient had intraabdominal
hemorrhage following a fall, and 1 patient had post-
procedural hemorrhage following colonoscopy and
HR (95% CI), 0.611 (0.455–0.822); p=.0010
289 273 261 255 244 236 232 229 222 218 212 207 202 198 196 183 96 34 2 






















Ibrutinib plus BR Placebo plus BR
Figure 3. Investigator-assessed OS for ibrutinib plus BR versus placebo plus BR.
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colon adenoma excision; none received anticoagu-
lants). Additionally, any grade TEAE incidences of
infections, neutropenia, diarrhea, anemia, hyperten-
sion, and atrial fibrillation, respectively, were 78.7%,
59.9%, 40.4%, 25.8%, 16.7%, and 11.8% in the ibrutinib
plus BR arm. Two (0.7%) patients in the ibrutinib plus
BR arm had grade 3 Aspergillus infections (onset of
events within the first and third year of treatment
with ibrutinib), 1 (0.3%) patient experienced a grade 2
cryptococcal infection (onset of event 7months after
starting ibrutinib treatment), and 2 (0.7%) patients had
Pneumocystis infections (1 grade 3; 1 grade 5; onset of
both events within the second year of treatment
with ibrutinib).
From the interim to final analysis, the prevalence of
TEAEs generally decreased over time (Figure 4).
Infections and infestations rates and other AEs
declined over time. Ventricular tachyarrhythmia rates
(3 patients; 1.0%), based on a Standardised MedDRA
Queries narrow search, were unchanged from the
interim analysis in the ibrutinib plus BR arm. In the
final analysis, 3 (1.0%) patients had cerebrovascular
accidents (2 grade 2; 1 grade 3). In the ibrutinib plus
BR arm, 5 (1.7%) patients had Richter’s transformation
(4 cases of large cell lymphoma and 1 case with
‘other’ histology). At the interim analysis, there were
no transformations in the ibrutinib group and 3 in the
placebo group. Overall, 74 (25.8%) patients in the ibru-
tinib plus BR arm died: 35 due to AEs, 11 of which
were related to study treatment (5 cases of infection,
2 cases of second malignancy [chronic myelomono-
cytic leukemia and myelodysplastic syndrome], and 1
case each of the following: multi-organ failure, sys-
temic inflammatory response syndrome, lung infiltra-
tion, aortic aneurysm rupture), 17 due to progressive
disease, and 22 due to other reasons (i.e. >30 days
after the last dose and not due to TEAEs/progres-
sive disease).
Discussion
In this final analysis of the HELIOS trial, median PFS
for patients with R/R CLL/SLL who received a median
of 2.0 prior lines of therapy (range 1–11) in the ibruti-
nib plus BR arm was 5.4 years. In this patient popula-
tion, HELIOS is the first study showing an OS benefit
with ibrutinib added to chemoimmunotherapy versus
chemoimmunotherapy alone [15].
At the time of the interim analysis (median follow-
up, 17months), ibrutinib plus BR significantly
improved PFS versus placebo plus BR for R/R CLL/SLL
[15]; IRC-assessed median PFS was not reached in the
ibrutinib plus BR arm versus 13.3months in the pla-
cebo plus BR arm (HR 0.203 [95% CI 0.150–0.276];
p< .0001). This final analysis confirms the persistent
benefit of ibrutinib plus chemoimmunotherapy;
median investigator-assessed PFS for the ibrutinib plus
BR arm was substantially longer than the placebo plus
BR arm (HR 0.229 [95% CI 0.183–0.286]; p< .0001). The
durability of PFS noted in our trial is consistent with
previously published observations in randomized trials
evaluating single-agent ibrutinib in comparable
patient populations and in patients with previously
untreated CLL [9,19].
Unlike the interim analysis of HELIOS, the 3-year
analysis showed an improved median OS with ibruti-
nib plus BR (HR 0.652 [95% CI 0.454–0.935]; p¼ .019).
In this final analysis, the long median PFS with ibruti-
nib plus BR translated into an OS benefit (HR 0.611
[95% CI 0.455–0.822]; p¼ .0010), despite 63.3% of
patients crossing over from the placebo plus BR arm
to ibrutinib treatment. The RESONATE study also




















Patients with any grade TEAEs 271 (94.4) 216 (87.8) 180 (83.3) 141 (75.0) 121 (70.8) 114 (72.6) 49 (38.0) 282 (98.3)
Patients with TEAEs of grade 3 212 (73.9) 111 (45.1) 87 (40.3) 62 (33.0) 37 (21.6) 35 (22.3) 17 (13.2) 259 (90.2)
Patients with any treatment-related TEAEa 225 (78.4) 145 (58.9) 122 (56.5) 76 (40.4) 68 (39.8) 50 (31.8) 21 (16.3) 249 (86.8)
Patients with any TESAE 104 (36.2) 47 (19.1) 53 (24.5) 40 (21.3) 29 (17.0) 29 (18.5) 13 (10.1) 198 (69.0)
Patients with any TEAE
leading to ibrutinib discontinuationb
22 (7.7) 15 (6.1) 8 (3.7) 3 (1.6) 3 (1.8) 2 (1.3) 5 (3.9) 58 (20.2)
Patients with any TEAEs
with a fatal outcomec
10 (3.5) 4 (1.6) 11 (5.1) 3 (1.6) 1 (0.6) 1 (0.6) 3 (2.3) 33 (11.5)
BR: bendamustine and rituximab; n: number of patients; TEAEs: treatment-emergent adverse events; TESAE: treatment-emergent serious adverse event.
aJudged by the investigator to be very likely, probably, possibly, or definitely related to the study drug.
bPatients who had TEAEs leading to discontinuation of ibrutinib were counted only at the interval when they discontinued ibrutinib.
cPatients who had TEAE leading to death were counted only at the interval when they died.
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demonstrated an OS benefit with ibrutinib versus ofa-
tumumab for R/R CLL/SLL (HR 0.639 [95% CI
0.418–0.975]) [10]. Additionally, median PFS2 was sub-
stantially longer for patients in the ibrutinib plus BR
arm despite crossover, further supporting the benefit
of earlier treatment with ibrutinib. Among the sub-
groups of patients who received subsequent therapies,
those who received ibrutinib as next treatment after
placebo plus BR had the longest time to next progres-
sion or death. For those who received other antineo-
plastic subsequent therapies, there was no meaningful
difference in time to next progression or death for
those who previously received ibrutinib plus BR or pla-
cebo plus BR, indicating that prior ibrutinib treatment
did not impact efficacy of subsequent therapy. The
small individual numbers of patients treated with spe-
cific alternative therapies do not allow a recommenda-
tion of a particular treatment for patients relapsing
after ibrutinib-based therapy, although responses,
including complete remissions, were observed in
patients treated with venetoclax regimens after ibruti-
nib plus BR.
Responses to ibrutinib plus BR in the HELIOS study
were durable and deepened over time. The final ana-
lysis also showed a significant increase in CR/CRi rate
(40.8%) compared with the interim analysis (21%),
reflecting the ongoing benefit of continuous treat-
ment with ibrutinib. The rate of undetectable MRD in
peripheral blood and bone marrow plateaued and
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Figure 4. Prevalence of any grade TEAEs over time in the ibrutinib arm for (A) TEAEs of clinical interest and (B) TEAEs occurring
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analysis, but 29% of patients had undetectable MRD
at the last analysis. The PFS curve did not show a plat-
eau at the final analysis, with a duration of follow-up
very close to the median PFS, despite deepening
responses over time.
Safety findings were consistent with known safety
profiles of ibrutinib and BR in patients with CLL
[9,20–22], and there were no unexpected findings at
the latest follow-up analysis compared with the 3-year
analysis. Consistent with prior analyses [15,16], this
extended 5-year follow-up analysis demonstrates the
manageable safety profile of ibrutinib. From the
interim results to final analysis, the prevalence of
TEAEs including serious TEAEs trended lower over
time with ibrutinib. However, it is notable that the
number of patients on treatment also decreased,
partly because of discontinuations due to AEs. Overall,
the prevalence of hypertension, atrial fibrillation, and
major hemorrhage events decreased over time
throughout the study. Rates of infections and infesta-
tions, including pneumonia, also declined over time
and the incidence of serious opportunistic infections,
e.g. Aspergillus, Cryptococcus, and Pneumocystis,
was low.
Our study is limited as it did not evaluate whether
ibrutinib plus BR is more beneficial than single-agent
ibrutinib in a relapsed setting. Nonetheless, an indirect
comparison of the RESONATE and HELIOS trials, after
adjusting for known confounding variables, has previ-
ously been published [23]. That analysis comparing
single-agent ibrutinib with ibrutinib plus BR suggested
that single-agent ibrutinib was superior for PFS and
OS. The analysis also suggested that an induction
period with BR did not improve outcomes, however,
only short-term follow-up of both trials was available
at the time of the published comparison, preventing
firm conclusions. Similarly, in a recently published
randomized trial in 208 patients with CLL (most [181]
with R/R CLL), ibrutinib plus rituximab did not improve
PFS versus single-agent ibrutinib despite faster remis-
sions and lower levels of residual disease in patients
receiving the combination. A recent study (Alliance
A041202) in patients with previously untreated CLL
also demonstrated no additional benefit of adding rit-
uximab to ibrutinib for PFS, in the first-line setting
[19]. However, due to differences in patient popula-
tions, study design, and treatment regimens, it is diffi-
cult to make indirect cross-trial comparisons.
Lack of resistance testing is another limitation of
this trial, as only a few genomic biomarker samples
were available. However, CLL remains an incurable dis-
ease and eventually the disease progresses further in
most patients with R/R CLL despite the therapy advan-
ces of previous years. Therefore, it is important to
assess adverse biologic features and resistance mecha-
nisms leading to treatment resistance in current and
future CLL studies to establish predictive biomarkers,
customize therapy, and enhance therapy outcomes.
In conclusion, with an extended median follow-up
of 63.7months, this final analysis confirms the long-
term safety and efficacy of ibrutinib plus BR in
patients with R/R CLL/SLL. In this patient population
with a median of 2.0 prior lines of therapy, median
PFS in the ibrutinib plus BR arm was 5.4 years and the
OS rate at 5 years was 75.7%. Long-term safety find-
ings for the ibrutinib plus BR arm were also consistent
with the known safety profiles of ibrutinib and BR and
support a positive benefit/risk profile for continuous
ibrutinib treatment.
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